磁性纳米颗粒MR靶向诊断乳腺癌的体外实验观察  

Preliminary study of breast cancer magnetic resonance targeting diagnosis basing on magnetic nanoparticles in vitro

作　　者：罗先富[1] 吴晶涛[1] 瞿秋霞[1] 胡晓华[1] 陈明祥[1] 陈文新[1] 董颖[1] 姜伦[1] 

机构地区：[1]江苏省苏北人民医院影像科,江苏扬州225001

出　　处：《中华医学杂志》2013年第35期2830-2833,共4页National Medical Journal of China

基　　金：基金项目：江苏省“333高层次人才培养工程”项目（BRA2010068）;扬州市社会发展科技攻关项目（YZ201008）

摘　　要：目的探讨CD40突变体抗体标记的磁性纳米颗粒与乳腺癌细胞结合在体外MR成像的可行性。方法采用化学交联法将单克隆抗体交联与超微超顺磁氧化铁（USPIO）粒子合成分子探针。通过流式细胞术、共聚焦显微镜及体外MR成像技术对探针与高表达CD40突变体乳腺癌细胞（M231）的靶向结合进行研究。MR信号变化数据组间比较采用单因素方差分析和LSD—t检验。结果携带磁性纳米颗粒的抗CIM0突变体分子探针被成功构建并分离，合成的探针同USPIO相比具有相似的磁学特性，具有良好的稳定性。分子探针能够特异性识别表达与乳腺癌细胞表面的CIM0突变体分子。体外磁共振成像显示探针同乳腺癌细胞结合后T2、T2值明显缩短[5H6-USPIO、5C11-USPIO、USPIO的T，分别为（51．66±5．31）、（92．89±4．72）、（64．56±3．85）ms]，T2图像较对照组明显变暗。实验组T2弛豫时间短于对照组，R弛豫时间差异有统计学意义。结论靶向CD40突变体的分子探针能够特异性识别乳腺癌细胞M231，可进一步用于动物体内靶向诊断成像。CD40突变体有望为乳腺癌MR分子成像提供新的靶点。Objective To develop a magnetic nanoparticles based magnetic resonance （MR） probe targeting CD40 mutant in the imaging of breast cancer cells in vitro. Methods For preparing an immunologically competent probe, monoclonal antibody was conjugated with ultrasmall superparamagnetic iron oxide （USPIO） particles basing on chemical cross-linking method. Its bioactivity was analyzed with flow cytometry, confocal microscopy and Prussian blue staining. The probe＇s cell MR imaging in vitro was conducted on breast cancer cells（ M231 ）high expressing CD40 mutant. The signal data from different groups were collected and analyzed with one-way variance and least significant difference-t test. Results The molecular probe carrying nanoparticles and CD40 mutant antibody was constructed and separated successfully. The probe had similar magnetic property compared with original USPIO particles. It could recognize CD40 mutant on breast cancer cells （M231） with high specificity. MR cell imaging in vitro shows that T2 and T2 ＊ obviously shortened after probe binding with M231 ceils and T2 weighted imaging become darker than control groups, the time of T2 is 5H6-USPIO （51.66±5.31 ）, 5C11-USPIO （ 92. 89±4.72 ）, USPIO（64. 56 ±3.85 ）ms. The T2 and T2 ＊ relaxation time of experiment group was shorter than control groups with statistical significance （ P 〈 0. 01 ）. Conclusion MR molecular probe targeting CD40 mutant may bind with breast cancer cells （ M231 ） to provide further in vivo animal MR imaging. And CD40 mutant is expected to provide a new target for MR molecular imaging of breast cancer.

关 键 词：乳腺肿瘤 抗原 CIMO 分子探针 

分 类 号：R737.9[医药卫生—肿瘤]